These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8821072)

  • 1. Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics.
    Baas H; Harder S; Demisch L; Bürklin F; Stecker K; Fischer PA
    J Neural Transm Suppl; 1995; 46():367-79. PubMed ID: 8821072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
    Okereke CS
    J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of levodopa.
    Nutt JG
    Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
    Harder S; Baas H
    Clin Pharmacol Ther; 1998 Aug; 64(2):183-91. PubMed ID: 9728899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
    Deleu D; Jacob P; Chand P; Sarre S; Colwell A
    Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
    Djaldetti R; Ziv I; Melamed E
    Isr J Med Sci; 1996 Dec; 32(12):1224-7. PubMed ID: 9007159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
    Harder S; Baas H; Rietbrock S
    Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.
    Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A
    Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic mechanisms of motor fluctuations.
    Sage JI; Mark MH
    Neurology; 1994 Jul; 44(7 Suppl 6):S10-4. PubMed ID: 8047256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dietary factors on levodopa pharmacokinetics.
    Fernandez N; Garcia JJ; Diez MJ; Sahagun AM; Díez R; Sierra M
    Expert Opin Drug Metab Toxicol; 2010 May; 6(5):633-42. PubMed ID: 20384552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.